STOCK TITAN

Avalyn Pharma COO Melissa Rhodes sells 13,300 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Avalyn Pharma Inc. Chief Operating Officer Melissa Rhodes exercised options for 13,300 common shares at an exercise price of $4.62 per share on November 17, 2026, then sold 13,300 shares under a Rule 10b5-1 trading plan adopted July 30, 2026. The reported weighted-average sale prices were $27.7918 per share for 10,875 shares, $28.2069 per share for 2,025 shares, and $29.2286 per share for 400 shares. Her reported option position after exercise was 170,638 shares.

Insider Rhodes Melissa
Role Chief Operating Officer
Sold 13,300 shs ($371K)
Approx. gross sale proceeds $371K
Approx. exercise cost $61K
Approx. pre-tax spread $310K
Share of Position Sold 100%
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F5 13,300 $0.00 $0.00
Exercise Common Stock F1 13,300 $4.62 $61K
Sale Common Stock F1, F2 10,875 $27.7918 $302K
Sale Common Stock F1, F3 2,025 $28.2069 $57K
Sale Common Stock F1, F4 400 $29.2286 $12K
Holdings After Transaction: Stock Option (Right to Buy) — 170,638 options (Direct); Common Stock — 0 shares (Direct)
Holdings Before and After: Stock Option (Right to Buy), 183,938 to 170,638 options (Direct); Common Stock, 0 to 0 shares (Direct)
Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (5)
  1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.10 to $28.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.10 to $28.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  4. F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.11 to $29.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  5. F5. 25% of the shares underlying this option vested and became exercisable on September 11, 2024, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Shares underlying options exercised 13,300 shares Melissa Rhodes's exercise on November 17, 2026
Option exercise price $4.62 per share Exercise on November 17, 2026
Shares sold 13,300 shares Three transactions on November 17, 2026
Weighted-average sale price $27.7918 per share 10,875 shares sold on November 17, 2026
Weighted-average sale price $28.2069 per share 2,025 shares sold on November 17, 2026
Weighted-average sale price $29.2286 per share 400 shares sold on November 17, 2026
Reported post-exercise option position 170,638 shares Following the November 17, 2026 transaction
Rule 10b5-1 trading plan regulatory
"the sales under a Rule 10b5-1 trading plan adopted July 30, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"the 10,875-share sale's reported weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
exercise price financial
"the options exercised at an exercise price of $4.62 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
substantially equal monthly installments technical
"the remaining 75% vested in substantially equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AVLN shares did Melissa Rhodes sell, and at what prices?

Melissa Rhodes sold 13,300 shares in three transactions on November 17, 2026, at weighted-average prices of $27.7918 per share for 10,875 shares, $28.2069 per share for 2,025 shares, and $29.2286 per share for 400 shares. The respective transaction-price ranges were $27.10 to $28.09, $28.10 to $28.93, and $29.11 to $29.37.

How many AVLN options did Melissa Rhodes exercise, and at what price?

She exercised options covering 13,300 common shares at a $4.62 exercise price on November 17, 2026. Her reported option position following the exercise was 170,638 shares.

What was the vesting schedule for Melissa Rhodes's AVLN option?

Twenty-five percent vested on September 11, 2024, and the remaining 75% vested in thirty-six substantially equal monthly installments thereafter, subject to Melissa Rhodes's continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rhodes Melissa

(Last)(First)(Middle)
C/O AVALYN PHARMA INC.
105 W FIRST STREET

(Street)
BOSTON MASSACHUSETTS 02127

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Avalyn Pharma Inc. [ AVLN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026M(1)13,300A$4.6213,300D
Common Stock11/17/2026S(1)10,875D$27.7918(2)2,425D
Common Stock11/17/2026S(1)2,025D$28.2069(3)400D
Common Stock11/17/2026S(1)400D$29.2286(4)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.6211/17/2026M(1)13,300 (5)01/24/2034Common Stock13,300$0.00170,638D
Explanation of Responses:
1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.10 to $28.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.10 to $28.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.11 to $29.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
5. 25% of the shares underlying this option vested and became exercisable on September 11, 2024, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
/s/ Douglas Carlson, Attorney-in-Fact11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading